The COVID-19 monoclonal antibody therapy Evusheld may not prevent COVID-19 caused by certain variants of the virus, the Food and Drug Administration announced this week. For details, see the updated fact sheet for health care providers
 
FDA last year authorized the combination monoclonal antibody therapy for emergency use to help prevent COVID-19 in certain adults and children with compromised immune systems or a history of severe adverse reaction to a COVID-19 vaccine or its components. FDA continues to recommend Evusheld to prevent COVID-19 as it still offers protection against many circulating variants, but encourages patients to be prepared to test and seek immediate treatment if they experience COVID-19 symptoms. The agency also continues to recommend that people who can get vaccinated and boosted to prevent COVID-19.
 

Related News Articles

Headline
The Food and Drug Administration does not currently authorize the monoclonal antibody bamlanivimab for emergency use to treat mild-to-moderate COVID-19 in the…
Headline
In a study of symptomatic adults tested for SARS-CoV-2 at U.S. pharmacies since Sept. 14, bivalent COVID-19 vaccine boosters provided additional protection…
Headline
The Biden Administration today launched a six-week campaign to encourage Americans to get an updated COVID-19 vaccine. In addition to ongoing pop-up clinics,…
Headline
The Health Resources and Services Administration this week opened the Provider Relief Fund reporting portal through Dec. 2 for health care providers…
Headline
Five medical organizations this week released a toolkit for clinicians in post-acute and long-term care settings about the benefits of the COVID-19 bivalent…
Headline
Children under age 5 are more likely to receive a COVID-19 vaccine if their parents perceive it as safe and their health care provider recommends it, according…